Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.14 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.